Expanded Programme on Immunization (EPI)

Size: px
Start display at page:

Download "Expanded Programme on Immunization (EPI)"

Transcription

1 Bhutan 2017 Expanded Programme on Immunization (EPI) FACT SHEET

2 Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles containing vaccine AFP Acute flaccid paralysis MICS Multiple indicator cluster survey BCG Bacillus Calmette-Guérin vaccine MMR Measles mumps rubella vaccine CES Coverage evaluation survey MNT Maternal and neonatal tetanus cmyp Comprehensive multi-year plan MR Measles rubella vaccine CRS Congenital rubella syndrome NCIP National committee on immunization practices DHS Demographic health survey NID National immunization day DT Diphtheria tetanus toxoid, pediatric NTAGI National technical advisory group on immunization DTP Diphtheria tetanus pertussis vaccine NPEV Non-polio enterovirus DTP-Hib-HepB Pentavalent vaccine NT Neonatal tetanus DTP-Hib-HepB3 3rd dose pentavalent vaccine OPV Oral poliovirus vaccine EPI Expanded programme on immunization bopv Bivalent OPV GDP Gross domestic product topv Trivalent OPV HCW Health care worker PCV Pneumococcal conjugate vaccine HepB Hepatitis B vaccine SEAR WHO South-East Asia Region Hib Haemophilus influenzae type b SIA Supplementary immunization activities HPV Human papilloma virus SNID Subnational immunization day IgM Immunoglobulin M Td Tetanus diphtheria toxoid; older children, adults IPV Inactivated poliovirus vaccine TT Tetanus toxoid JE Japanese encephalitis TT2+ 2 or more doses TT JE_Live-Atd JE live attenuated vaccine VDPV Vaccine derived poliovirus JRF WHO UNICEF joint reporting form VPD Vaccine preventable diseases LB Live birth WCBA Women of child bearing age M Measles WPV Wild poliovirus

3 Contents Impact of routine immunization EPI history 5 Basic information 2016 Table 1 5 Immunization schedule 2016 Table 2 5 National immunization coverage Figure 1 6 Immunization system highlights Table 3 6 DTP3 coverage, diphtheria and pertussis cases Figure 2 7 Reported cases of vaccine preventable diseases Table 4 7 DTP-Hib-HepB3 coverage by district 2015 Figure 3 7 DTP-Hib-HepB3 coverage by district 2016 Figure 4 7 Maternal and neonatal tetanus elimination is sustained TT2+ coverage and NT cases Figure 5 8 Polio-free status is maintained Page No. Page No. Page No. AFP surveillance indicators Table 5 9 Non-polio AFP rate by district 2015 Figure 6 9 Non-polio AFP rate by district 2016 Figure 7 9 Adequate stool specimen collection percentage by district 2015 Figure 8 10 Adequate stool specimen collection percentage by district 2016 Figure 9 10 OPV supplementary immunization activities Table 6 10 Towards measles elimination and rubella/congenital rubella syndrome control Page No. MCV1 and MCV2 coverage, measles and rubella cases, Figure MCV supplementary immunization activities Table 7 11 MCV1 coverage by district 2015 Figure MCV1 coverage by district 2016 Figure MCV2 coverage by district 2015 Figure MCV1 coverage by district 2016 Figure Immunity against measles immunity profile by age in 2016 Figure Subnational risk assessment for measles and rubella Figure Sporadic and outbreak associated measles cases by month Figure Immunization status of confirmed (laboratory and Epi linked) measles outbreak associated cases by age Figure Quality of field and laboratory surveillance for measles and rubella Table 8 14 Performance of laboratory surveillance Table 9 14 WHO supported laboratory network for VPD surveillance Figure 19 15

4 WHO South-East Asia Region Bhutan: district level map Disclaimer: The boundaries and names shown and the designations used on all the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area of its authorities, or concerning the delimitation of its frontiers or boundaries. 4

5 Impact of routine immunization Table 1: Basic information EPI history EPI launched on 15 November 1979 TT for pregnant women introduced in 1983 HepB vaccine introduced in 1997 DTP-HepB vaccine introduced in 2003 AD syringes introduced in 2003 MR vaccine introduced in 2006 DTP-Hib-HepB vaccine introduced in 2009 HPV vaccine introduced in 2010 HepB birth dose introduced in 2012 TT vaccine replaced by Td vaccine in 2012 IPV vaccine introduced in 2015 topv to bopv switched on 25 April 2016 MMR vaccine introduced in October Source: cmyp and VPDP/MOH Total population 757,042 Live births 12,869 Children <1 year 11,227 Children <5 years 82,561 Children <15 years 229,796 Pregnant women 11,680 WCBA (15-49 years) 186,509 Neonatal mortality rate 18.3 (per 1,000 LB) Infant mortality rate (per 1,000 LB) Under-five mortality rate 32.9 (per 1,000 LB) Maternal mortality ratio (per 100,000 LB) 1 SEAR annual EPI reporting form, 2016 and WHO, World Health Statistics VPDP/MOH Table 2: Immunization schedule, 2016 Vaccine Age of administration BCG Birth HepB Birth OPV Birth, 6 weeks, 10 weeks and 14 weeks DTP-Hib-HepB 6 weeks, 10 weeks and 14 weeks IPV 14 weeks MMR 9 months and 24 months DTP 24 months HPV Females 12 years and grade VI girls Td 6 and 12 years Vitamin A 6 to 30 months (6 months interval) Source: WHO/UNICEF JRF,, Division/Province/State/Region - Dzongkhag/District 20 Gewog/Block 205 Sub-block/Ward 1,050 Village (approx.) 3,717 Population density (per sq. km) 18 Population living in urban areas 37% Population using improved drinkingwater sources % Population using improved sanitation % Total expenditure on health as % of GDP 3.6% Births attended by skilled health 74.6% personnel 2 Neonates protected at birth against NT 83%

6 Figure 1: National immunization coverage, % Coverage BCG DTP OPV MCV Source: WHO/UNICEF estimates of national immunization coverage, July 2017 revision Table 3: Immunization system highlights cmyp for immunization NTAGI fully functional Spending on vaccines financed by the government 41% Spending on routine immunization programme financed by the government 24% Updated micro-plans that include activities to improve immunization coverage 20 districts (100%) National policy for health care waste management including waste from immunization activities National system to monitor AEFI in place in place Most recent EPI CES National Health Survey 2012 >80% coverage for DTP-Hib-HepB3 20 districts (100%) >90% coverage for MCV1 16 districts (80%) >10% drop-out rate for DTP-Hib-HepB1 to DTP-Hib-HepB3 1 district (5%) Source: WHO/UNICEF JRF,

7 Figure 2: DTP3 coverage 1, diphtheria and pertussis cases 2, DTP-Hib-HepB3 coverage by district Figure 3: No. of cases % Coverage Source: SEAR annual EPI reporting form, 2015 (administrative data) Year Diphtheria Cases Pertussis Cases DTP3 Coverage 1 WHO/UNICEF estimates of national immunization coverage, July 2017 revision 2 WHO vaccine-preventable diseases: monitoring system 2016 Figure 4: 2016 Table 4: Reported cases of vaccine preventable diseases, Year Polio Diphtheria Pertussis NT (% of all tetanus) Measles Rubella Mumps JE CRS ND Source: SEAR annual EPI reporting form, 2016 (administrative data) Source: WHO/UNICEF JRF, (multiple years) ND=No data <70% 70% - 79% 80% - 89% > 90% 7

8 Maternal and neonatal tetanus elimination is sustained Figure 5: TT2+ coverage 1 and NT cases 2, MNT elimination before 2000 No. of cases No data Year % Coverage NT Cases TT2+ Coverage 1 WHO/UNICEF JRF, Country official estimates, WHO vaccine-preventable diseases: monitoring system

9 Polio-free status is maintained Table 5: AFP surveillance performance indicators, Last clinically-confirmed polio case was reported in Indicator AFP cases Wild poliovirus confirmed cases Compatible cases Non-polio AFP rate Adequate stool specimen collection percentage 2 83% 70% 80% 73% 67% 73% Total stool samples collected % NPEV isolation % Timeliness of primary result reported Number of discarded AFP cases per 100,000 children under 15 years of age. 2 Percent with 2 specimens, at least 24 hours apart and within 14 days of paralysis onset. 3 Results reported within 14 days of sample received at laboratory. Non-polio AFP rate by district Figure 6: 2015 Figure 7: 2016 WHO/Bhutan/S Bahadur < >2 No non-polio AFP case 9

10 Adequate stool specimen collection % by district Figure 8: 2015 Figure 9: 2016 <60% 60% - 79% >80% No AFP Table 6: OPV SIAs Year Vaccine Geographic coverage Target age Target population Coverage (%) Round 1 Round 2 Round 1 Round OPV NID <5 years 80, OPV SNID <5 years 37, OPV SNID <5 years 37, OPV SNID <5 years 36, OPV SNID <5 years 36, OPV SNID <5 years 38, OPV SNID <5 years 36, OPV SNID <5 years 37, Source: WHO/UNICEF JRF, (multiple years) 10

11 Towards measles elimination and rubella/crs control Figure 10: MCV1 and MCV2 coverage 1, measles and rubella cases 2, Table 7: MCV SIAs Year Antigen Geographic coverage Target group Target Coverage % M nationwide 9 months to 15 years 69, % No. of cases % Coverage 2000 M nationwide 2006 MR nationwide 9 months to 15 years 9 months to 14 years children and 15 years to 44 years women 214, % 338,040 98% Year Measles Cases Rubella MCV1 Coverage MCV2 Coverage 2016 MR subnational % Source: WHO/UNICEF (multiple years) 1 WHO/UNICEF estimates of national immunization coverage, July 2017 revision 2 WHO vaccine-preventable diseases: monitoring system

12 MCV1 coverage by district MCV2 coverage by district Figure 11: 2015 Figure 12: 2016 Figure 13: 2015 Figure 14: 2016 Source: SEAR annual EPI reporting form, 2015 (administrative data) Source: SEAR annual EPI reporting form, 2016 (administrative data) Source: SEAR annual EPI reporting form, 2015 (administrative data) Source: SEAR annual EPI reporting form, 2016 (administrative data) <80% 80% - 89% 90% - 94% >95% Figure 15: Immunity against measles - immunity profile by age in 2016 Figure 16: Sub-national risk assessment - measles and rubella Percent of population 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Age (in years) Protected by maternal antibodies Protected by routine vaccination with 1st dose Protected by routine vaccination with 2nd dose Protected by SIAs Immune due to past infection Susceptible * Modeled using MSP tool ver 2 assuming the schedule and MCV coverage remain unchanged and no SIAs between 2009 & Very high risk High risk Medium risk Low risk Not available Source: developed using WHO risk assessment tool based on JRF & ARF data base

13 Figure 17: Sporadic and outbreak associated measles cases* by month Sporadic measles Outbreak associated measles an-11 ar-11 ay-11 ul-11 ep-11 ov-11 an-12 ar-12 ay-12 ul-12 ep-12 ov-12 an-13 *Includes laboratory confirmed and epidemiologically linked cases Source: SEAR Monthly VPD reports. ar-13 Figure 18: Immunization status of confirmed (laboratory and EPI linked) measles outbreak associated cases, by age, ay-13 ul-13 ep-13 ov-13 an-14 ar-14 ay-14 ul-14 ep-14 ov-14 an-15 ar-15 ay-15 ul-15 ep-15 ov-15 an-16 ar-16 ay-16 ul-16 ep-16 ov WHO/Bhutan/S Bahadur 2 0 < 1 year 1-4 years 5-9 years years > 15 years < 1 year 1-4 years 5-9 years years > 15 years < 1 year 1-4 years 5-9 years years > 15 years < 1 year 1-4 years 5-9 years years > 15 years < 1 year 1-4 years 5-9 years years > 15 years < 1 year 1-4 years 5-9 years years > 15 years Immunized Not immunized/ Unknown Source: SEAR annual EPI reporting form ( ) 13

14 Table 8: Surveillance performance indicators for measles and rubella, Case classification (number) Indicators Year No. of suspected measles Lab-confirmed Measles EPI-linked Clinically-confirmed Lab-confirmed Rubella EPI-linked Discarded non-measles non-rubella cases Annual incidence of confirmed measles cases per million total population Annual incidence of confirmed rubella cases per million total population Proportion of all suspected measles and rubella cases that have had an adequate investigation initiated within 48 hours of notification Discarded non-measles non-rubella incidence per 100,000 total population Proportion of districts reporting at least two discarded non-measles non-rubella cases per 100,000 total population Proportion of sub-national surveillance units reporting to the national level on time Target % 2 80% 80% ND ND ND ND ND ND ND ND 3 ND ND 14 ND ND Source: SEAR annual EPI reporting form, ND=No data Table 9: Performance of laboratory surveillance, Year Serum specimen collected from suspected measles cases Serum specimen received in laboratory within 5 days of collection Specimen positive for measles IgM Specimen positive for rubella IgM % Results within 4 days of receipt % Positive cases tested for viral detection No (%) No (%) No. % No. % Measles Rubella (100) 50 (81) 1 1% 2 2% (100) 57 (69) 0 0% 6 6% (100) 30 (43) 0 0% 4 6% (100) 120 (100) 11 9% 1 1% (100) 146 (100) 40 27% 3 2% ND ND ND ND Source: SEAR annual EPI reporting form, ND=No data Genotypes detected 14

15 Figure 19: WHO supported laboratory network for VPD surveillance Public Health Laboratory National measles/rubella laboratory National Japanese encephalitis laboratory 15

16 For contact or feedback: Expanded Programme on Immunization Ministry of Health, Thimphu, Bhutan Tel: , Fax: Immunization and Vaccine Development (IVD) WHO-SEARO, IP Estate, MG Marg, New Delhi , India Tel: , Fax:

Expanded Programme on Immunization (EPI)

Expanded Programme on Immunization (EPI) Timor-Leste 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles

More information

Expanded Programme on Immunization (EPI)

Expanded Programme on Immunization (EPI) Indonesia 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles

More information

Expanded Programme on Immunization (EPI)

Expanded Programme on Immunization (EPI) Sri Lanka 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles

More information

Table 1: Basic information Total population 25,030, (per 100,000 LB) Division/Province/State/Region 11. District 210

Table 1: Basic information Total population 25,030, (per 100,000 LB) Division/Province/State/Region 11. District 210 EPI history EPI launched in 980 HepB vaccine introduced in 003 AD syringes introduced in 003 HepB birth dose introduced in 004 DTP-HepB vaccine introduced in 006 MCV introduced in 008 DTP-Hib-HepB vaccine

More information

Table 1: Basic information 2017

Table 1: Basic information 2017 EPI history EPI launched in 978 OPV and MCV introduced in 987 AD syringes introduced in 00 HepB vaccine introduced in 003 MCV introduced partially in 008 and made available nationwide in 0 DTP-Hib-HepB

More information

Table 1: Basic information (per 1,000 LB) 42.4 (per 1,000 LB) 49.7 (per 1,000 LB) 215 (per 100,000 LB)

Table 1: Basic information (per 1,000 LB) 42.4 (per 1,000 LB) 49.7 (per 1,000 LB) 215 (per 100,000 LB) EPI history EPI started in 978 EPI re-structured in March 000 DTP-HepB vaccine introduced in 007 DTP-Hib-HepB)vaccine introduced in 0 MR vaccine introduced in Feb 06 Second dose of MR introduced in Feb

More information

Total population 24,759,000. Live births (LB) 342,458. Children <1 year 337,950. Children <5 years 1,698,664. Children <15 years 5,233,093

Total population 24,759,000. Live births (LB) 342,458. Children <1 year 337,950. Children <5 years 1,698,664. Children <15 years 5,233,093 DPR Korea 4 Immunization system highlights There is a comprehensive multiyear plan (cmyp) for immunization covering -5. A standing national technical advisory group on immunization (NTAGI) with formal

More information

Table 1: Basic information ,000, (per 1,000 LB) 34.6 (per 1,000 LB) 174 (per 100,000 LB) District 712.

Table 1: Basic information ,000, (per 1,000 LB) 34.6 (per 1,000 LB) 174 (per 100,000 LB) District 712. EPI history EPI launched in 978 with DPT, OPV, BCG and typhoid vaccines TT immunization of pregnant women introduced in 983 MCV introduced in 985 HepB piloted in 00 and made universal in 0 MCV introduced

More information

Total population 1,212,110. Live births (LB) 43,924. Children <1 year 40,351. Children <5 years 192,340. Children <15 years 510,594

Total population 1,212,110. Live births (LB) 43,924. Children <1 year 40,351. Children <5 years 192,340. Children <15 years 510,594 Draft version for the SEAR-ITAG 5-9 June 5 All data provisional as of May 5 Timor Leste 4 Immunization system highlights There is a comprehensive multi-year plan (cmyp) for immunization covering 3-5. 8%

More information

Total population 20,675,000. Live births (LB) 349,715. Children <1 year 346,253. Children <5 years 1,778,050. Children <15 years 5,210,100

Total population 20,675,000. Live births (LB) 349,715. Children <1 year 346,253. Children <5 years 1,778,050. Children <15 years 5,210,100 Sri Lanka 4 Immunization system highlights There is a comprehensive multi-year plan (cmyp) for immunization system strengthening covering -6. A national policy on immunization has been developed. A standing

More information

Total population 1,265,308,000. Live births (LB) 27,016,000. Children <1 year 25,928,200. Children <5 years 23,818,000. Children <15 years 25,639,000

Total population 1,265,308,000. Live births (LB) 27,016,000. Children <1 year 25,928,200. Children <5 years 23,818,000. Children <15 years 25,639,000 India 4 Immunization system highlights There is a comprehensive multiyear plan (cmyp) for immunization covering 3-7. National technical advisory group on immunization (NTAGI) exists and formal written

More information

Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG)

Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG) Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG) Background India was certified polio-free along with 10 other countries of WHO South-East Asia Region

More information

Afghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision

Afghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision Afghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data

More information

Immunization and Vaccine Development (IVD) SEARO

Immunization and Vaccine Development (IVD) SEARO Monthly Vaccine Preventable Disease and Immunization Update Published: January 03, 2018 Immunization and Vaccine Development (IVD) SEARO Protecting People from Vaccine Preventable Diseases Last wild poliovirus

More information

Monthly Vaccine Preventable Disease and Immunization Update Published: May 11, 2018 Immunization and Vaccine Development (IVD) SEARO

Monthly Vaccine Preventable Disease and Immunization Update Published: May 11, 2018 Immunization and Vaccine Development (IVD) SEARO Monthly Vaccine Preventable Disease and Immunization Update Published: May 11, 2018 Immunization and Vaccine Development (IVD) SEARO Protecting People from Vaccine Preventable Diseases Last wild poliovirus

More information

Joint National/International Expanded Programme on Immunization and Vaccine Preventable Disease Surveillance Review

Joint National/International Expanded Programme on Immunization and Vaccine Preventable Disease Surveillance Review SEA-Immun-97 Distribution: General Joint National/International Expanded Programme on Immunization and Vaccine Preventable Disease Surveillance Review Democratic Socialist Republic of 16 26 October 2015

More information

The Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007

The Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007 History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we

More information

Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision

Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data received

More information

National HPV Vaccine Coverage, WHO- UNICEF Joint Reporting Form

National HPV Vaccine Coverage, WHO- UNICEF Joint Reporting Form resource from : Evaluating HPV vaccination pilots: practical experience from path publication title National HPV Vaccine Coverage, WHO- UNICEF Joint Reporting Form publisher WHO/UNICEF publication date

More information

Selected vaccine introduction status into routine immunization

Selected vaccine introduction status into routine immunization Selected introduction status into routine infant immunization worldwide, 2003 This report summarizes the current status of national immunization schedules in 2003, as reported by Member States in the /UNICEF

More information

Pakistan: WHO and UNICEF estimates of immunization coverage: 2017 revision

Pakistan: WHO and UNICEF estimates of immunization coverage: 2017 revision Pakistan: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data received

More information

Immunizations are among the most cost effective and widely used public health interventions.

Immunizations are among the most cost effective and widely used public health interventions. Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean

More information

Monthly Vaccine Preventable Disease and Immunization Update Published: March 10, 2015 Immunization and Vaccine Development (IVD) SEARO

Monthly Vaccine Preventable Disease and Immunization Update Published: March 10, 2015 Immunization and Vaccine Development (IVD) SEARO Monthly Vaccine Preventable Disease and Immunization Update Published: March 10, 2015 Immunization and Vaccine Development (IVD) SEARO Protecting People from Vaccine Preventable Diseases Last wild poliovirus

More information

Requirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination.

Requirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination. Requirements for new trials to examine offtarget effects of vaccination Workshop on: Off-target (heterologous/non-specific) effects of vaccination Les Pensieres Jun 8-10, 2015 PEM Fine London School of

More information

Immunization Update & focus on meningococcal vaccine PART 1

Immunization Update & focus on meningococcal vaccine PART 1 Immunization Update & focus on meningococcal vaccine PART 1 Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases University of Cape Town www.vacfa.uct.ac.za Disclosures Received

More information

WHO Library Cataloguing-in-Publication Data. World health statistics 2011.

WHO Library Cataloguing-in-Publication Data. World health statistics 2011. WORLD HEALTH STATISTICS 2011 WHO Library Cataloguing-in-Publication Data World health statistics 2011. 1.Health status indicators. 2.World health. 3.Health services - statistics. 4.Mortality. 5.Morbidity.

More information

GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012

GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012 GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012 ADRESSING CHALLENGES TO SUSTAINABLE NEW VACCINE INTRODUCTION: PERSPECTIVE FROM MONGOLIA N.UDVAL, MD, Sc D MINISTER OF HEALTH MONGOLIA CONTENT

More information

Targeted Diseases and Immunization. Strategic plan

Targeted Diseases and Immunization. Strategic plan Targeted Diseases and Immunization Strategic plan 2008-2013 Communicable Diseases Unit WHO Regional Office for Europe Mission To provide technical support to WHO European Region Member States to ensure

More information

Task Force on Immunization (TFI) in Africa 14 th Annual Meeting. And. Africa Regional Inter-Agency Coordination Committee (ARICC) 13 th Annual Meeting

Task Force on Immunization (TFI) in Africa 14 th Annual Meeting. And. Africa Regional Inter-Agency Coordination Committee (ARICC) 13 th Annual Meeting Task Force on Immunization (TFI) in Africa 14 th Annual Meeting And Africa Regional Inter-Agency Coordination Committee (ARICC) 13 th Annual Meeting Meeting Report Maputo, Mozambique 27 29 November 2006

More information

South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) Meeting Report

South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) Meeting Report The eighth meeting of the World Health Organization's South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) was held from 13 to 16 June 2017 in New Delhi, India. SEAR-ITAG is a technical

More information

Ministry of Health Viet Nam

Ministry of Health Viet Nam Ministry of Health Viet Nam National Expanded Program on Immunization Comprehensive Multi-Year Plan cmyp for Extended Program on Immunization 2016-2020 Ha Noi, August 2015 Contents Acronyms... 1 Executive

More information

OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE

OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE Dr Tiong Wei Wei, MD, MPH Senior Assistant Director Policy and Control Branch, Communicable Diseases Division Ministry of Health 9

More information

SEA-Immun-105 Distribution: General. WHO South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG)

SEA-Immun-105 Distribution: General. WHO South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) SEA-Immun-105 Distribution: General WHO South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) Report of the Seventh Meeting of SEAR-ITAG New Delhi, India, 7 10 June 2016 World Health

More information

Measles and Rubella Fact Sheet SEAR #

Measles and Rubella Fact Sheet SEAR # and Fact Sheet SEAR 8-9 Table : South-East Asia Regional (SEAR) Strategic Plan 7- Goal: To reduce the number of measles deaths by 9 in relative to estimates. Objectives: Achieve at least 9 national Containing

More information

Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation

Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Background Information Immunisation services in Syria Syria had good immunisation services,

More information

C o n t e n t s. > Immunizations 4. > Diphtheria 6. > Pertussis 7. > Tetanus 8. > Polio 9. > Measles 10. > Tuberculosis 11.

C o n t e n t s. > Immunizations 4. > Diphtheria 6. > Pertussis 7. > Tetanus 8. > Polio 9. > Measles 10. > Tuberculosis 11. C o n t e n t s > Immunizations 4 > Diphtheria 6 > Pertussis 7 > Tetanus 8 > Polio 9 > Measles 1 > Tuberculosis 11 > Hepatitis B 12 > Rubella and CRS 13 > Haemophius Influenza B 14 I m m u n i z a t i

More information

Evaluating Immunisation Dropout Rates in Eight Hard to Reach Unions of Maulvibazar District, Bangladesh

Evaluating Immunisation Dropout Rates in Eight Hard to Reach Unions of Maulvibazar District, Bangladesh International Journal of Immunology 2017; 5(1): 5-10 http://www.sciencepublishinggroup.com/j/iji doi: 10.11648/j.iji.20170501.12 ISSN: 2329-177X (Print); ISSN: 2329-1753 (Online) Evaluating Immunisation

More information

Polio Eradication in India. Dr Sunil Bahl Deputy Project Manager WHO Country Office for India 28 October 2014

Polio Eradication in India. Dr Sunil Bahl Deputy Project Manager WHO Country Office for India 28 October 2014 Polio Eradication in India Dr Sunil Bahl Deputy Project Manager WHO Country Office for India 28 October 2014 History of Polio in India Number of Cases 200,000 200,000 OPV Introduced in RI - 1978 150,000

More information

Immunization and Vaccine Development (IVD) SEARO

Immunization and Vaccine Development (IVD) SEARO VPD Update for Week 33, 2014 Data as of 18 August 2014 Immunization and Vaccine Development (IVD) SEARO Protecting People from Vaccine Preventable Diseases Last wild poliovirus case by type, SEAR WPV Type

More information

Towards the Achievement of GHSA 2024 s Overarching Targets

Towards the Achievement of GHSA 2024 s Overarching Targets 정보화파트업무계획 [GHSA] Immunization Towards the Achievement of GHSA 2024 s Overarching Targets 2016년추진업무및 2017년업무계획 ( 사업관리 ) 7 th November 2018 Korea Centers for Disease Control and Prevention I. Overview Contents

More information

CHILDHOOD VACCINATION

CHILDHOOD VACCINATION EPI (3) Age of Child How and Where is it given? CHILDHOOD VACCINATION Nicolette du Plessis Block 10 28/02/2012 10 weeks DTaP-IPV/Hib (2) Diphtheria, Tetanus, Acellular pertussis, Inactivated polio vaccine,

More information

Current National Immunisation Schedule Dr Brenda Corcoran National Immunisation Office.

Current National Immunisation Schedule Dr Brenda Corcoran National Immunisation Office. Current National Immunisation Schedule 2012 Dr Brenda Corcoran National Immunisation Office Objectives To outline immunisation schedules in Ireland Primary childhood schedule Vaccine uptake rates School

More information

EPI and VPD Surveillance Review and Post-Introduction Evaluation of Hib (Pentavalent) Vaccine

EPI and VPD Surveillance Review and Post-Introduction Evaluation of Hib (Pentavalent) Vaccine EPI and VPD Surveillance Review and Post-Introduction Evaluation of Hib (Pentavalent) Vaccine Report of the Mission Bangladesh, 15-25 March 2012 Regional Office for South-East Asia SEA-Immun-67 Distribution:

More information

Draft Programme (05 May 2016)

Draft Programme (05 May 2016) Innovations in sustainable Draft Programme (05 May 2016) Draft 7 th Meeting of the South-East Asia Region Immunization Technical Advisory Group (SEAR ITAG) 6-10 June 2016, New Delhi (India) Day 1, Monday,

More information

Why still Polio Donato Greco ECDC polio consultant 14 April 2016

Why still Polio Donato Greco ECDC polio consultant 14 April 2016 Why still Polio Donato Greco ECDC polio consultant 14 April 2016 A medical student with the last texbook on Communicable diseases! Where there is no chapter on Poliomielitis!!! What can I say o Background

More information

Global Report to SAGE. Fulfillment of previous recommendations & progress highlights

Global Report to SAGE. Fulfillment of previous recommendations & progress highlights Global Report to SAGE Fulfillment of previous recommendations & progress highlights SAGE Meeting, 8-10 November 2012 J.M. Okwo-Bele, WHO Outline 1 2 3 4 Global progress Regional updates- RTAGs recommendations

More information

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020. Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy

More information

Update on Transition: the case of Honduras. Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016

Update on Transition: the case of Honduras. Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016 Update on Transition: the case of Honduras Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016 GAVI Support for Honduras Content Honduras EPI Situation 2011-2016 Vaccination

More information

Public Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04.

Public Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04. ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many Medical Policy Title: Immunization Coverage Document: ARB0454:04 Administered by: Public Statement: 1.

More information

New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines

New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines Antigens Vaccine Approved Age Daptacel Diphtheria, Tetanus, and acellular Pertussis (DTaP)

More information

WHITE PAPER. A Summary of Global Immunization Coverage through David W Brown, Anthony H Burton, Marta Gacic-Dobo (alphabetical order)

WHITE PAPER. A Summary of Global Immunization Coverage through David W Brown, Anthony H Burton, Marta Gacic-Dobo (alphabetical order) WHITE PAPER A Summary of Global Immunization Coverage through 2013 David W Brown, Anthony H Burton, Marta Gacic-Dobo (alphabetical order) for the WHO and UNICEF working group for monitoring national immunization

More information

WHO/UNICEF Review of National Immunization Coverage India

WHO/UNICEF Review of National Immunization Coverage India WHO/UNICEF Review of National Immunization Coverage 1980-2002 India October, 2003 India Estimates, 1980-2002 80 66 68 73 73 60 40 30 20 10 0 1980 19 1982 1983 1984 1985 1986 1987 1988 1989 19 1991 1992

More information

This document was published by: The National Department of Health. Editorial team: Provincial EPI Team National EPI Team Dr NJ Ngcobo

This document was published by: The National Department of Health. Editorial team: Provincial EPI Team National EPI Team Dr NJ Ngcobo REVISED : OCTOBER 2010 This document was published by: The National Department of Health Editorial team: Provincial EPI Team National EPI Team Dr NJ Ngcobo Copies may be obtained from: The National Department

More information

Challenges of building a new vaccine delivery platform for LMICs

Challenges of building a new vaccine delivery platform for LMICs Challenges of building a new vaccine delivery platform for LMICs Terri B. Hyde, MD MPH Immunizations Systems Branch, GID, CDC 23 March 2017 Immunization in the Elderly Geneva, Switzerland What has been

More information

Mongolia s Comprehensive Multi-Year Plan for Immunization ( )

Mongolia s Comprehensive Multi-Year Plan for Immunization ( ) Draft of Third Edition (4 May 2007) Mongolia s Comprehensive Multi-Year Plan for Immunization (2007-2012) Khuvsgul Bayan-Ulgii Uv Khovd Zavkha Arkhangai Seleng Bulga Darkhan- Orkhon! Tu Khentii Dornod

More information

Vaccine Preventable Disease Surveillance: Overview. Thomas Cherian, WHO

Vaccine Preventable Disease Surveillance: Overview. Thomas Cherian, WHO Vaccine Preventable Disease Surveillance: Overview Thomas Cherian, WHO Global Framework on Immunization Monitoring and Surveillance (GFIMS) l An extension of the GIVS, published on December 07 - http://www.who.int/immunization/en/

More information

Thailand Expanded Program on Immunization. Suchada Jiamsiri, MD, MPH Division of Vaccine Preventable Diseases Ministry of Public Health, Thailand

Thailand Expanded Program on Immunization. Suchada Jiamsiri, MD, MPH Division of Vaccine Preventable Diseases Ministry of Public Health, Thailand Thailand Expanded Program on Immunization Suchada Jiamsiri, MD, MPH Division of Vaccine Preventable Diseases Ministry of Public Health, Thailand Outline Expanded Program on Immunization Organization Immunization

More information

Global Health Policy: Vaccines

Global Health Policy: Vaccines Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY

More information

Preventing Vaccine-Preventable Diseases in HIV-Infected Children and Adults

Preventing Vaccine-Preventable Diseases in HIV-Infected Children and Adults Preventing Vaccine-Preventable Diseases in HIV-Infected Children and Adults 1. Objective The objectives of this chapter are to underline the role of vaccination in reducing morbidity and mortality in HIV

More information

1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector

1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector 1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share

More information

Meeting Report June 2018 Manila, Philippines

Meeting Report June 2018 Manila, Philippines Meeting Report 27TH MEETING OF THE TECHNICAL ADVISORY GROUP ON IMMUNIZATION AND VACCINE-PREVENTABLE DISEASES IN THE WESTERN PACIFIC REGION 19 22 June 2018 Manila, Philippines WORLD HEALTH ORGANIZATION

More information

VACCINE DIALOGUE AIDC 2017

VACCINE DIALOGUE AIDC 2017 VACCINE DIALOGUE AIDC 2017 Idea is Not to discuss about each vaccine Discuss about when to use- clinical situations Allaying the fears ADULT VACCINES Question What are the current CDC recommendations on

More information

UIP FACT SHEET. Socio - demographic profile PRL. Infant Mortality Rate

UIP FACT SHEET. Socio - demographic profile PRL. Infant Mortality Rate UIP FACT SHEET WEST BENGAL Census 1 Total Population 8,176,197 Population--6yr 11,414,222 Literacy Rate 68.6 Sex Ratio 934 Sex Ratio -6 yr 96 Socio - demographic profile Census 11 91,347,736 1,112,599

More information

CPT 2016 Code Changes

CPT 2016 Code Changes CPT 2016 Code Changes Code Changes - Medicine New CPT 2016 New Codes Code Description 69209 Removal impacted cerumen using irrigation/lavage, unilateral 90620 Meningococcal recombinant protein and outer

More information

WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC

WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC REPORT SIXTEENTH MEETING OF THE TECHNICAL ADVISORY GROUP ON IMMUNIZATION AND VACCINE PREVENTABLE DISEASES IN THE WESTERN PACIFIC REGION

More information

7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids

7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids 7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids Contents Introduction Nunavut Recommended Childhood Immunization Schedule Nunavut Routine Adult Immunization Schedule Nunavut Immunization

More information

School Nurse Regional Update School Year Immunizations COLORADO IMMUNIZATION BRANCH

School Nurse Regional Update School Year Immunizations COLORADO IMMUNIZATION BRANCH School Nurse Regional Update 2017-18 School Year Immunizations COLORADO IMMUNIZATION BRANCH Talking Points Child Care Immunizations K through 12 th Grade Immunizations Official Medical and Non-Medical

More information

3. CONCLUSIONS AND RECOMMENDATIONS

3. CONCLUSIONS AND RECOMMENDATIONS 3. CONCLUSIONS AND RECOMMENDATIONS 3.1 Polio Endgame Strategy Conclusions 1. The TAG welcomes the RCC conclusion that Western Pacific Region maintains its polio-free status, and commends China for the

More information

Vaccines and other immunological antimicrobial therapy 1

Vaccines and other immunological antimicrobial therapy 1 Vaccines and other immunological antimicrobial therapy 1 Vaccines Vaccine: a biological preparation that provides active acquired immunity to a particular disease. Vaccine typically contains an agent that

More information

Poliomyelitis: successful and critical issues in the eradication process

Poliomyelitis: successful and critical issues in the eradication process Vaccine Preventable Diseases in the Mediterranean Basin and Black Sea: immunization strategies and coverage in the general population and the newly arrived migrants the ProVacMed project Poliomyelitis:

More information

Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office

Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office SAGE, Geneva 27 October 2009 Rebecca Martin Targeted Diseases and

More information

Royal Government of Bhutan Ministry of Health Department of Public Health Vaccine Preventable Disease Program

Royal Government of Bhutan Ministry of Health Department of Public Health Vaccine Preventable Disease Program Royal Government of Bhutan Ministry of Health Department of Public Health Vaccine Preventable Disease Program COMPREHENSIVE MULTI-YEAR PLAN OF IMMUNIZATION 2014 2018 Annex E Table of Contents Executive

More information

Pertussis. (Whole-cell pertussis vaccines) must not be frozen, but stored at 2 8 C. All wp vaccines have an expiry date of months.

Pertussis. (Whole-cell pertussis vaccines) must not be frozen, but stored at 2 8 C. All wp vaccines have an expiry date of months. Program Management 61_5 The wp vaccines have a considerably lower price than ap vaccines and, where resources are limited and the vaccine is well accepted by the local population, wp vaccine remains the

More information

Immunizations for Children and Teens with Suppressed Immune Systems

Immunizations for Children and Teens with Suppressed Immune Systems Immunizations for Children and Teens with Suppressed Immune Systems Your child is starting treatment that will suppress the immune system. This will affect how your child s body responds to routine immunizations

More information

Expanded Programme on Immunization (EPI):

Expanded Programme on Immunization (EPI): Expanded Programme on Immunization (EPI): Introduction Four to five million annual deaths could be prevented by 2015 through sustained and appropriate immunization efforts, backed by financial support.

More information

Benefit Interpretation

Benefit Interpretation Benefit Interpretation Subject: Part B vs. Part D Vaccines Issue Number: BI-039 Applies to: Medicare Advantage Effective Date: May 1, 2017 Attachments: Part B Vaccines Diagnosis Code Limits Table of Contents

More information

Measles. Phases of accelerated measles control activities (measles mortality reduction and measles elimination) are indicated in Appendix 80_5.

Measles. Phases of accelerated measles control activities (measles mortality reduction and measles elimination) are indicated in Appendix 80_5. Program Management 80_1 With renewed global commitment to achieving measles mortality reduction, the 2003 World Health Assembly stressed the importance of achieving the goals adopted by the United Nations

More information

Expanded Programme on Immunization

Expanded Programme on Immunization 1 Expanded Programme on Immunization Strategic issues Immunization is a cost-effective public health intervention that has dramatically reduced disease, disability and death in the Western Pacifi c Region.

More information

RECOMMENDED IMMUNIZATIONS

RECOMMENDED IMMUNIZATIONS Recommended Immunization Schedule for Persons Aged 0 Through 6 Years United States 2010 1 2 4 6 12 15 18 19 23 2 3 4 6 Vaccine Age Birth month months months months months months months months years years

More information

Measles and Rubella Global Update SAGE 19 October 2017

Measles and Rubella Global Update SAGE 19 October 2017 Measles and Rubella Global Update SAGE 19 October 2017 Alya Dabbagh WHO HQ, IVB/EPI Global update Overview Regional progress and challenges M&RI Midterm Review updates Economics of measles and rubella

More information

Programme update. Prequalification of Vaccines

Programme update. Prequalification of Vaccines Programme update Prequalification of Vaccines UN Prequalification of Medicines, Diagnostics and Vaccines 6th Consultative Stakeholder Meeting 4 April 2011 David Wood, WHO/IVB/QSS Outline Good news - A

More information

ANNUAL HEALTH SCREENINGS AND IMMUNIZATIONS GUIDE MEN WOMEN ALL ADULTS CHILDREN

ANNUAL HEALTH SCREENINGS AND IMMUNIZATIONS GUIDE MEN WOMEN ALL ADULTS CHILDREN AND IMMUNIZATIONS GUIDE MEN WOMEN ALL ADULTS CHILDREN MEN PROSTATE CANCER Testicular exam Age 18+ PSA test Ages 50-75, based on risk WOMEN BREAST CANCER Self breast exam Monthly Clinical breast exam Annually

More information

DCVMN AND VACCINE SECURITY IN ASEAN REGION. ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014.

DCVMN AND VACCINE SECURITY IN ASEAN REGION. ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014. DCVMN AND VACCINE SECURITY IN ASEAN REGION ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014. Phuket - Thailand Developing Countries Vaccine Manufacturers Network (DCVMN)

More information

immunisation in New Zealand

immunisation in New Zealand This appendix details the history of. Section A1.1 is a brief summary of when each vaccine was introduced to the National Immunisation Schedule (the Schedule). This summary includes vaccines which were

More information

GLOBAL IMMUNIZATION COVERAGE IN 2016

GLOBAL IMMUNIZATION COVERAGE IN 2016 NATIONAL IMMUNIZATION COVERAGE SCORECARDS ESTIMATES FOR 2016 GLOBAL IMMUNIZATION COVERAGE IN 2016 In May 2012, the Sixty-fifth World Health Assembly endorsed the Global Vaccine Action Plan (GVAP) for the

More information

Cyprus Experience. Dr. Elena Papamichael Ministry of Health

Cyprus Experience. Dr. Elena Papamichael Ministry of Health Cyprus Experience Dr. Elena Papamichael Ministry of Health Cyprus became independent on1960. On 1974, Turkish troops invaded in the island disturbing the willing for peaceful living. Since then, Turkey

More information

WHO Library Cataloguing-in-Publication Data. World health statistics 2015.

WHO Library Cataloguing-in-Publication Data. World health statistics 2015. WHO Library Cataloguing-in-Publication Data World health statistics 2015. 1.Health status indicators. 2.World health. 3.Health services - statistics. 4.Mortality. 5.Morbidity. 6.Life expectancy. 7.Demography.

More information

WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC

WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC REPORT SEVENTEENTH MEETING OF THE TECHNICAL ADVISORY GROUP ON IMMUNIZATION AND VACCINE PREVENTABLE DISEASES IN THE WESTERN PACIFIC REGION

More information

Joint National/International Review of Acute Flaccid Paralysis (AFP) Surveillance Nepal

Joint National/International Review of Acute Flaccid Paralysis (AFP) Surveillance Nepal SEA Polio 44 Distribution: Limited Joint National/International Review of Acute Flaccid Paralysis (AFP) Surveillance Nepal 25 March 6 April 2006 and 6-12 August 2006 World Health Organization This document

More information

The schedule for childhood vaccination is:(web link to NHS Childhood Immunisation Schedule for 2008

The schedule for childhood vaccination is:(web link to NHS Childhood Immunisation Schedule for 2008 Immunisations and vaccinations Immunisation is an effective public health intervention for promoting good health and protecting individuals and populations against serious disease and infection through

More information

WHY WE RE HERE. Melinda Wharton, MD, MPH Director, Immunization Services Division. National Center for Immunization & Respiratory Diseases

WHY WE RE HERE. Melinda Wharton, MD, MPH Director, Immunization Services Division. National Center for Immunization & Respiratory Diseases National Center for Immunization & Respiratory Diseases WHY WE RE HERE Melinda Wharton, MD, MPH Director, Immunization Services Division AIM Leadership Conference February 8, 2017 Vaccines save lives.

More information

REPORT Of the FIRST SOUTH-EAST ASIA REGIONAL TECHNICAL ADVISORY GROUP ON IMMUNIZATION (SEAR ITAG) MEETING July 2008 Bangkok, Thailand

REPORT Of the FIRST SOUTH-EAST ASIA REGIONAL TECHNICAL ADVISORY GROUP ON IMMUNIZATION (SEAR ITAG) MEETING July 2008 Bangkok, Thailand 1 REPORT Of the FIRST SOUTH-EAST ASIA REGIONAL TECHNICAL ADVISORY GROUP ON IMMUNIZATION (SEAR ITAG) MEETING 14-15 July 2008 Bangkok, Thailand 2 First South-East Asia Regional Technical Advisory Group on

More information

POLIO ERADICATION AND POST-CERTIFICATION STRATEGY

POLIO ERADICATION AND POST-CERTIFICATION STRATEGY POLIO ERADICATION AND POST-CERTIFICATION STRATEGY PRE-BOARD MEETING 5 June 2018, Geneva Reach every child www.gavi.org Agenda Topic Presenter 1. Polio eradication update WHO 10 minutes 2. IPV supply, demand

More information

Preparing for the withdrawal of all oral polio vaccines (OPVs): Replacing trivalent OPV with bivalent OPV

Preparing for the withdrawal of all oral polio vaccines (OPVs): Replacing trivalent OPV with bivalent OPV Preparing for the withdrawal of all oral polio vaccines (OPVs): Replacing trivalent OPV with bivalent OPV Frequently Asked Questions February 2015 Table of Contents Rationale for OPV cessation... 2 About

More information

Communicable Disease & Immunization

Communicable Disease & Immunization Communicable Disease & Immunization Ingham County Health Surveillance Book 2016 Communicable Disease & Immunization - 1 Communicable Disease & Immunization T he control of communicable disease and immunization,

More information

Protecting people from Vaccine Preventable Diseases

Protecting people from Vaccine Preventable Diseases Protecting people from Vaccine Preventable Diseases Immunization and Vaccine Development South East Asia Region Strategic Plan (2010 2013) Table of Contents INTRODUCTION...2 1. THE IVD MISSION IN THE GLOBAL

More information

APPENDIX EE VACCINE STATUS AND DATE

APPENDIX EE VACCINE STATUS AND DATE VACCINE STATUS AND DATE Vaccine Status, Date is a ten-character field which presents information about each of the vaccines required for children. For most cases, the first character tells the vaccine

More information

KURUKSHETRA JULY 2017 RURAL HEALTH

KURUKSHETRA JULY 2017 RURAL HEALTH KURUKSHETRA JULY 2017 RURAL HEALTH Jagat Prakash Nadda is the Union Minister of Health and Family Welfare. Immunization, or immunisation, is the process by which an individual's immune system becomes

More information

Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch

Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch Polio Partners Group meeting Geneva 8 December 2014 Michel Zaffran Coordinator, WHO/EPI, IMG Co-chair On behalf

More information

Guideline for the immunization of HIV infected persons in Sri Lanka

Guideline for the immunization of HIV infected persons in Sri Lanka DOI: http://doi.org/10.4038/joshhm.v3i0.64 Guideline for the immunization of HIV infected persons in Sri Lanka Dr. M. K. Darshanie Mallikarachchi, Consultant Venereologist, Provincial General Hospital

More information